参考文献/References:
[1] Whiting DR,Guariguata L,Weil C,et al.IDF diabetes atlas:global estimates of the prevalence of diabetes for 2011 and 2030[J].Diabetes Res Clin Pract,2011,94(3):311-321.DOI:10.1016/j.diabres.2011.10.029.
[2] Fombang EN,Saa RW.Antihyperglycemic activity of moringa oleifera lam leaf functional tea in rat models and human subjects [J].Food Nutri Sci,2016,7(11):1020-1032.DOI:10.4236/fns.2016.711099.
[3] 申其玲,李春君.胰岛β细胞再生治疗糖尿病的研究进展[J].国际内分泌代谢杂志,2018,38(4):267-270.DOI:10.3760/cma.j.issn.1673-4157.2018.04.012.
[4] Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycaemia in type 2 diabetes,2015:a patient-centred approach.Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes [J].Diabetologia,2015,58(3):429-442.DOI:10.1007/s00125-014-3460-0.
[5] Resnick HE,Foster GL,Bardsley J,et al.Achievement of American Diabetes Association clinical practice recommendations among U.S.adults with diabetes,1999-2002:the National Health and Nutrition Examination Survey [J].Diabetes Care,2006,29(3):531-537.DOI:10.2337/diacare.29.03.06.dc05-1254.
[6] Ruban A,Uthayakumar A,Ashrafian H,et al.Endoscopic interventions in the treatment of obesity and diabetes[J].Dig Dis Sci,2018,63(7):1694-1705.DOI:10.1007/s10620-018-5117-1.
[7] Brunaldi VO,Galvao Neto M.Endoscopic techniques for weight loss and treating metabolic syndrome[J].Curr Opin Gastroenterol,2019,35(5):424-431.DOI:10.1097/MOG.0000000000000561.
[8] Johnston MP,Buchanan RM,Patel J,et al.Reduction of HbA1c in patients with type 2 diabetes following duodenal mucosal resurfacing:could other factors be at play [J].Gut,2020,69(12):2260-2261.DOI:10.1136/gutjnl-2020-320900.
[9] Haidry RJ,van Baar AC,Galvao Neto MP,et al.Duodenal mucosal resurfacing:proof-of-concept,procedural development,and initial implementation in the clinical setting[J].Gastrointest Endosc,2019,90(4):673-681,e2.DOI:10.1016/j.gie.2019.03.024.
[10] Hadefi A,Huberty V,Lemmers A,et al.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes [J].Dig Dis,2018,36(4):322-324.DOI:10.1159/000487078.
[11] van Baar ACG,Beuers U,Wong K,et al.Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes:6-month multicentre results[J].JHEP Rep,2019,1(6):429-437.DOI:10.1016/j.jhepr.2019.10.006.
[12] van Baar ACG,Holleman F,Crenier L,et al.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus:one year results from the first international,open-label,prospective,multicenter study[J].Gut,2020,69(2):295-303.DOI: 10.1136/gutjnl-2019-318349.
[13] Popov VB,Ou A,Schulman AR,et al.Thompson CC:The impact of intragastric balloons on obesity-related co-morbidities:a systematic review and metaanalysis[J].Am J Gastroenterol,2017,112(3):429-439.DOI:10.1038/ajg.2016.530.
[14] Tate CM,Geliebter A.Intragastric balloon treatment for obesity:FDA safety updates[J].Adv Ther,2018,35(1):1-4.DOI:10.1007/s12325-017-0647-z.
[15] Kindel TL,Yoder SM,Seeley RJ,et al.Duodenal-jejunal exclusion improves glucose tolerance in the diabetic,Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism[J].J Gastrointest Surg,2009,13(10):1762-1772.DOI:10.1007/s11605-009-0912-9.
[16] Sullivan S,Swain JM,Woodman G,et al.Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity:the ESSENTIAL trial[J].Obesity(Silver Spring),2017,25(2):294-301.DOI:10.1002/oby.21702.
[17] Lopez-Nava G,Sharaiha RZ,Vargas EJ,et al.Endoscopic sleeve gastroplasty for obesity:a multicenter study of 248 patients with 24 months follow-up[J].Obes Surg,2017,27(10):2649-2655.DOI:10.1007/s11695-017-2693-7.
[18] Rajagopalan H,Cherrington AD,Thompson CC,et al.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes:6-month interim analysis from the first-in-human proof-of-concept study[J].Diabetes Care,2016,39(12):2254-2261.DOI:10.2337/dc16-0383.
[19] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.DOI:10.1002/hep.28431.
[20] Zelber-Sagi S,Godos J,Salomone F.Lifestyle changes for the treatment of nonalcoholic fatty liver disease:a review of observational studies and intervention trials[J].Therap Adv Gastroenterol,2016,9(3):392-407.DOI:10.1177/1756283X16638830.
[21] Friedman SL,Neuschwander-Tetri BA,Rinella M,et al.Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.DOI:10.1038/s41591-018-0104-9.
[22] Younus H,Sharma A,Miquel R,et al.Bariatric surgery in cirrhotic patients:is it safe [J].Obes Surg,2019,30(4):1241-1248.DOI:10.1007/s11695-019-04214-7.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(02):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(02):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(02):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(02):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(02):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(02):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(02):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(02):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(02):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(02):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]